1. Recent Articles

    1. Genetic susceptibility to neuroblastoma: current knowledge and future directions.

      Genetic susceptibility to neuroblastoma: current knowledge and future directions.

      Cell Tissue Res. 2018 Mar 27;:

      Authors: Ritenour LE, Randall MP, Bosse KR, Diskin SJ

      Abstract Neuroblastoma, a malignancy of the developing peripheral nervous system that affects infants and young children, is a complex genetic disease. Over the past two decades, significant progress has been made toward understanding the genetic determinants that predispose to this often lethal childhood cancer.

      Read Full Article
      Mentions: ALK PHOX2B
    2. Alteration of Serum IgG Galactosylation as a Potential Biomarker for Diagnosis of Neuroblastoma.

      Alteration of Serum IgG Galactosylation as a Potential Biomarker for Diagnosis of Neuroblastoma.

      J Cancer. 2018;9(5):906-913

      Authors: Qin W, Pei H, Qin R, Zhao R, Han J, Zhang Z, Dong K, Ren S, Gu J

      Abstract Background: Neuroblastoma (NB) is the most frequent pediatric malignant neoplasm that originates from embryonic neural crest cells.

      Read Full Article
    3. Treatment and outcome of adult-onset neuroblastoma.

      Treatment and outcome of adult-onset neuroblastoma.

      Int J Cancer. 2018 Mar 25;:

      Authors: Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, Hammond WJ, LaQuaglia MP, Wolden SL, Cheung NV, Modak S

      Abstract Adult-onset of neuroblastoma is rare and little is known about its biology and clinical course. There is no established therapy for adult neuroblastoma.

      Read Full Article
    4. Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.

      Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.

      Biochem Biophys Res Commun. 2018 Mar 20;:

      Authors: Xu DQ, Toyoda H, Qi L, Morimoto M, Hanaki R, Iwamoto S, Komada Y, Hirayama M

      Abstract Mammalian target of rapamycin (mTOR) complex (mTORC) is frequently activated in diverse cancers. Although dual mTORC1/2 inhibitors are currently under development to treat various malignancies, the emergence of drug resistance has proven to be a major complication.

      Read Full Article
    5. Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Cell Tissue Res. 2018 Mar 23;:

      Authors: Tolbert VP, Matthay KK

      Abstract Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life.

      Read Full Article
      Mentions: Treatment MYCN
    6. Prenatally detected thoracic neuroblastoma.

      Prenatally detected thoracic neuroblastoma.

      Obstet Gynecol Sci. 2018 Mar;61(2):278-281

      Authors: Park Y, Lee HJ, Jung YJ, Lee JH, Kwon JY, Kim YH

      Abstract Neuroblastoma is the most common pediatric extracranial solid tumor derived from primitive neural crest cells of the sympathetic nervous system. Although one-fifths of all neuroblastomas occurs within the thorax, thoracic neuroblastomas detected in fetus have been rarely reported.

      Read Full Article
    7. Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Korean J Pediatr. 2018 Feb;61(2):53-58

      Authors: Kim C, Choi YB, Lee JW, Yoo KH, Sung KW, Koo HH

      Abstract Purpose: Although the prognosis is generally good in patients with intermediate-risk neuroblastoma, no consensus has been reached on the ideal treatment regimen.

      Read Full Article
    8. Successful Use of Extracorporeal Life Support in a Hematopoietic Stem Cell Transplant Patient with Neuroblastoma.

      Successful Use of Extracorporeal Life Support in a Hematopoietic Stem Cell Transplant Patient with Neuroblastoma.

      J Extra Corpor Technol. 2018 Mar;50(1):61-64

      Authors: Williams FZ, Vats A, Cash T, Fortenberry JD

      Abstract Respiratory failure associated with hematopoietic stem cell transplantation (HSCT) has been considered a contraindication for use of extracorporeal membrane oxygenation (ECMO) at many centers.

      Read Full Article
    9. Pediatric mandibular metastasis: A rare finding of neuroblastoma.

      Pediatric mandibular metastasis: A rare finding of neuroblastoma.

      Radiol Case Rep. 2018 Feb;13(1):289-294

      Authors: Wade G, Revels J, Hartman L, Brown W

      Abstract We present a case of metastatic neuroblastoma to the mandible in an 11-month-old patient presenting with worsening right-sided proptosis and scalp swelling after a fall 2 weeks prior. Initial evaluation with computed tomography of the head demonstrated soft tissue masses centered at the right sphenoid and right mandible.

      Read Full Article
      Mentions: Metastasis
    10. Metabolic profiling of the three neural derived embryonal pediatric tumors retinoblastoma, neuroblastoma and medulloblastoma, identifies distinct metabolic profiles.

      Metabolic profiling of the three neural derived embryonal pediatric tumors retinoblastoma, neuroblastoma and medulloblastoma, identifies distinct metabolic profiles.

      Oncotarget. 2018 Feb 16;9(13):11336-11351

      Authors: Kohe SE, Bennett CD, Gill SK, Wilson M, McConville C, Peet AC

      Read Full Article
    11. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.

      Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.

      Transfusion. 2018 Mar 13;:

      Authors: Ceppi F, Rivers J, Annesley C, Pinto N, Park JR, Lindgren C, Mgebroff S, Linn N, Delaney M, Gardner RA

      Read Full Article
    12. See all articles
  2. Comments

  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (2 articles) MYCN
    2. (2 articles) ALK
    3. (2 articles) Treatment
    4. (1 articles) Antibody
    5. (1 articles) PHOX2B
  3. Recent Quotes

    1. We continue to expand our broad array of proprietary T cell programming technologies designed to tackle specific aspects of tumour biology and we are pleased to highlight the article published in Molecular Therapy about our novel small-molecule-activated permanent off switch.
      By Christian Itin
    2. We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells.
      By Gregory Szeto
    3. The antigen-presenting capabilities of B cells have often been underestimated, but they are being increasingly appreciated for their practical advantages in therapies.
      By Gail Bishop
    4. Our dream is to spawn out a whole class of therapies which involve taking out your own cells, telling them what to do, and putting them back into your body to fight your disease, whatever that may be.
      By Armon Sharei
    5. We envision a future system, if we can take advantage of its microfluidic nature, as a bedside or field-deployable device.
      By Armon Sharei
    6. Down the road, you could potentially get enough cells from just a normal syringe-based blood draw, run it through a bedside device that has the antigen you want to vaccinate against, and then you'd have the vaccine.
      By Gregory Szeto
    7. The problem is that unlike blood, a skin sample or even a tissue biopsy, you can't take a piece of a patient's neural system. It runs like complex wiring throughout the body and portions cannot be sampled for study.
      By Mick Bhatia
    8. Now we can take easy to obtain blood samples, and make the main cell types of neurological systems - the central nervous system and the peripheral nervous system - in a dish that is specialized for each patient.
      By Mick Bhatia
    9. If I was a patient and I was feeling pain or experiencing neuropathy, the prized pain drug for me would target the peripheral nervous system neurons, but do nothing to the central nervous system, thus avoiding non-addictive drug side effects.
      By Mick Bhatia
    10. This bench to bedside research is very exciting and will have a major impact on the management of neurological diseases, particularly neuropathic pain.
      By Akbar Panju